TEVA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Teva Pharmaceutical Industries's interest expense for the three months ended in Dec. 2023 was $ -221 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-1,029 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Teva Pharmaceutical Industries's Operating Income for the three months ended in Dec. 2023 was $ 1,286 Mil. Teva Pharmaceutical Industries's Interest Expense for the three months ended in Dec. 2023 was $ -221 Mil. Teva Pharmaceutical Industries's Interest Coverage for the quarter that ended in Dec. 2023 was 5.82. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Teva Pharmaceutical Industries's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,029 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries (NYSE:TEVA) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Teva Pharmaceutical Industries's Interest Expense for the three months ended in Dec. 2023 was $-221 Mil. Its Operating Income for the three months ended in Dec. 2023 was $1,286 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $18,481 Mil.
Teva Pharmaceutical Industries's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
Interest Coverage | = | -1 | * | Operating Income (Q: Dec. 2023 ) | / | Interest Expense (Q: Dec. 2023 ) |
= | -1 | * | 1286 | / | -221 | |
= | 5.82 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Dov Bergwerk | officer: Acting Chief Legal Officer | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Vikki L Conway | officer: See "Remarks" | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Varda Shalev | director | MATAM PARK, BUILDING #5, HAIFA L3 3508409 |
Eliyahu Sharon Kalif | officer: EVP, Chief Financial Officer | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Amir Weiss | officer: Chief Accounting Officer | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Angus Grant | officer: EVP, Business Development | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Eric A Hughes | officer: See "Remarks" | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Sven Dethlefs | officer: EVP Global Marketing&Portfolio | 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Eric Drape | officer: Executive VP Global Operations | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
David Matthew Stark | officer: Exec. VP Chief Legal Officer | 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Richard Daniell | officer: Exec. VP, European Commercial | 5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033 |
Richard D Francis | officer: President and CEO | IM LANGACHER 44, GREIFENSEE V8 8606 |
Hafrun Fridriksdottir | officer: Executive VP, Global R&D | 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054 |
Eli Shani | officer: EVP,Global Marketing&Portfolio | C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033 |
Tal Zvi Zaks | director | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
From GuruFocus
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.